✨ Free AI Report
Aktis Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Aktis Oncology, Inc.
Research Preview

Aktis Oncology, Inc.: Business Overview, Financials & Competitive Analysis

Aktis Oncology (NASDAQ:AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platfo...

Analyst-debate audio for Aktis Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for Aktis Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aktis Oncology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Well-capitalized clinical-stage radiopharmaceutical company with proprietary platform, multiple Phase 1b trials underway, and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aktis Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Aktis Oncology, Inc. Overview

Pro stress-test →

Aktis Oncology (NASDAQ:AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies. Prior to its IPO, Aktis banked $346 million in private funding to advance its pipeline of radiopharmaceuticals, including investments from MPM BioImpact, Vida Ventures and RA Capital.

Strategic Profile

Pro stress-test →

The Company has built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy to a broader range of patient populations. Aktis' most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer.

Competitive Landscape

Pro stress-test →

Aktis targets well-established tumor antigens; AKY-1189 targets Nectin-4, the same protein targeted by Pfizer's Padcev in bladder cancer. Key competitors in radiopharmaceutical oncology include established radioligand therapy developers and emerging miniprotein-based platforms.

Industry Context

Aktis Oncology, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2020 · Headquarters: Boston, Massachusetts · Employees: 76 full-time employees as of September 2025 · Revenue: $8.28M (trailing 12 months as of March 31, 2026); estimated $0 commercial revenue (clinical-stage company) · Market cap: $1.3B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aktis Oncology, Inc..

+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Aktis Oncology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

NovartisRadiopharmaceutical for neuroendocrine tumors→Advanced Accelerator ApplicationsRadiopharmaceutical developer for neuroendocrine and oncology applications→Lantheus HoldingsMedical imaging and radiopharmaceutical company→TeranosticsRadiopharmaceutical company developing targeted cancer treatments→Ayala PharmaceuticalsOncology-focused biopharmaceutical company with radiopharmaceutical programs→

Compare Aktis Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aktis Oncology, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Aktis Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aktis Oncology, Inc. and its top competitor on Cyborg Score”
“What did Aktis Oncology, Inc. do this quarter?”
“Is Aktis Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aktis Oncology, Inc. do?+
Aktis Oncology (NASDAQ:AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platfo...
What is Aktis Oncology, Inc.'s Cyborg Score?+
Aktis Oncology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aktis Oncology, Inc.'s main competitors?+
Named competitors include Novartis, Advanced Accelerator Applications, Lantheus Holdings, Teranostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Aktis Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aktis Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aktis Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.